KEAP1 and non-small cell lung carcinoma: Subgroup analyses from POSEIDON and CheckMate 227 suggest that adding a CTLA-4 inhibitor may improve outcomes in metastatic NSCLC with STK11 and KEAP1 mutations (47, 48).